A single-institution demographic study of pathologically proven renal disease in kidney transplant recipients over the last 33 years
Journal of Pathology and Translational Medicine · 15.07.2026 · 60 (4) · 398-412
DOI: 10.4132/jptm.2026.03.28 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pathology and Translational Medicine, erschienen am 15.07.2026. Verfasst von Hyejin Noh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Korea Medical Device Development Fund, Ministry of Science and ICT, Ministry of Trade, Industry and Energy.
Abstract (Originalsprache)
Background
While the number of kidney transplants for end-stage renal disease (ESRD) is increasing, studies examining the long-term demographic analyses based on pathological diagnosis of transplant kidney remain limited.
Methods
We conducted a retrospective analysis of 4,188 transplant recipients who underwent either biopsy or nephrectomy from 1991 to 2023 at Seoul St. Mary’s Hospital.
Results
Among 7,229 pathologically confirmed cases, rejection was the most prevalent (37.7%), followed by tubulointerstitial (25.4%), glomerular, drug toxicity, and vascular diseases. In 7,053 transplant biopsies, rejection was predominant across all age groups, with T-cell mediated (TCM) category being the most common (60.1%), followed by antibody-mediated and mixed. Drug toxicity increased with age (p = .047), while glomerular and tubulointerstitial diseases were highest in recipients under 20 (p < .001). Among glomerular diseases, IgA-related glomerulonephritis (45.2%) was the most common. In 176 transplant nephrectomies, the most common diagnosis was rejection (33.5%), followed by renal infarction (19.9%), tubulointerstitial, vascular, glomerular disease, and drug toxicity. “Others” included infarction, ESRD, and lymphangiectasia, which increased with age (p = .011). In nephrectomy cases, rejection decreased over time, with chronic TCM rejection (40.7%) being the most frequent.
Conclusions
This study provides valuable insights into transplant kidney disease in South Korea. The number of transplant biopsies has increased over the past 33 years, while the number of nephrectomies has remained unchanged. Rejection was the most common finding in all age groups in biopsies, but decreased with age in nephrectomies, with TCM being the most common and observed more often in younger recipients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. mdyjchoi@catholic.ac.kr.
Förderung
- Korea Medical Device Development Fund
- Ministry of Science and ICT
- Ministry of Trade, Industry and Energy
- Ministry of Health and Welfare
- Ministry of Food and Drug Safety
Zitieren
APA
Noh, H., Kim, J., & Choi, Y. J. (2026). A single-institution demographic study of pathologically proven renal disease in kidney transplant recipients over the last 33 years. Journal of Pathology and Translational Medicine, 60(4), 398-412. https://doi.org/10.4132/jptm.2026.03.28
Vancouver
Noh H, Kim J, Choi YJ. A single-institution demographic study of pathologically proven renal disease in kidney transplant recipients over the last 33 years. Journal of Pathology and Translational Medicine. 2026;60(4):398-412. doi:10.4132/jptm.2026.03.28
BibTeX
@article{Noh2026,
author = {Noh, Hyejin and Kim, Jiyeon and Choi, Yeong Jin},
title = {A single-institution demographic study of pathologically proven renal disease in kidney transplant recipients over the last 33 years},
journal = {Journal of Pathology and Translational Medicine},
year = {2026},
volume = {60},
number = {4},
pages = {398--412},
doi = {10.4132/jptm.2026.03.28}
}
EUVIMED